Show simple item record

dc.contributor.authorWheatley-Price, P
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorLee, Siow Ming
dc.contributor.authorMa, C
dc.contributor.authorAshcroft, Linda
dc.contributor.authorJitlal, M
dc.contributor.authorQian, W
dc.contributor.authorHackshaw, A
dc.contributor.authorRudd, R
dc.contributor.authorBooton, Richard
dc.contributor.authorDanson, Sarah
dc.contributor.authorLorigan, Paul C
dc.contributor.authorThatcher, Nick
dc.contributor.authorShepherd, F A
dc.date.accessioned2010-07-13T09:12:25Z
dc.date.available2010-07-13T09:12:25Z
dc.date.issued2010-03-23
dc.identifier.citationThe influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. 2010:Ann Oncolen
dc.identifier.issn1569-8041
dc.identifier.pmid20332134
dc.identifier.doi10.1093/annonc/mdq067
dc.identifier.urihttp://hdl.handle.net/10541/107554
dc.description.abstractBACKGROUND: Some non-small-cell lung cancer (NSCLC) surgical series have indicated that the positive prognostic effect of female sex is limited to patients with adenocarcinoma. We carried out a retrospective analysis to investigate the role of sex and histology on efficacy, toxicity, and dose delivery after chemotherapy. Patient and methods: Individual patient data were pooled from five randomized, phase III, advanced NSCLC chemotherapy trials. Primary outcomes were response rate, overall survival (OS), toxicity, and dose delivery. A secondary analysis examined survival by sex in histological subgroups. RESULTS: Of 2349 patients, 34% were women. Women had a higher response rate to chemotherapy (42% versus 40%, P = 0.01) and longer survival than men (median OS 9.6 versus 8.6 months, P = 0.002). The difference in OS remained after adjusting for age, stage, performance status, and histology (hazard ratio 0.83, 95% confidence interval 0.74-0.92, P = 0.0005). Upon further examination, longer survival in women was only seen in patients with adenocarcinoma (test for interaction P = 0.006). There were no differences in hematological toxicity or transfusions. Women experienced more grade 3-4 emesis than men (P < 0.0001) and more dose delays (P = 0.02) or dose reductions (P < 0.0001). CONCLUSION: The positive prognostic effect among women is confirmed in patients receiving platinum-based chemotherapy but appears confined to those with adenocarcinoma histology.
dc.languageENG
dc.language.isoenen
dc.subjectChemotherapyen
dc.subjectHistologyen
dc.subjectLung Canceren
dc.subjectSexen
dc.titleThe influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials.en
dc.typeArticleen
dc.contributor.departmentPrincess Margaret Hospital/University Health Network, Toronto, Ontario, Canada.en
dc.identifier.journalAnnals of Oncologyen
refterms.dateFOA2020-04-03T11:14:30Z
html.description.abstractBACKGROUND: Some non-small-cell lung cancer (NSCLC) surgical series have indicated that the positive prognostic effect of female sex is limited to patients with adenocarcinoma. We carried out a retrospective analysis to investigate the role of sex and histology on efficacy, toxicity, and dose delivery after chemotherapy. Patient and methods: Individual patient data were pooled from five randomized, phase III, advanced NSCLC chemotherapy trials. Primary outcomes were response rate, overall survival (OS), toxicity, and dose delivery. A secondary analysis examined survival by sex in histological subgroups. RESULTS: Of 2349 patients, 34% were women. Women had a higher response rate to chemotherapy (42% versus 40%, P = 0.01) and longer survival than men (median OS 9.6 versus 8.6 months, P = 0.002). The difference in OS remained after adjusting for age, stage, performance status, and histology (hazard ratio 0.83, 95% confidence interval 0.74-0.92, P = 0.0005). Upon further examination, longer survival in women was only seen in patients with adenocarcinoma (test for interaction P = 0.006). There were no differences in hematological toxicity or transfusions. Women experienced more grade 3-4 emesis than men (P < 0.0001) and more dose delays (P = 0.02) or dose reductions (P < 0.0001). CONCLUSION: The positive prognostic effect among women is confirmed in patients receiving platinum-based chemotherapy but appears confined to those with adenocarcinoma histology.


Files in this item

Thumbnail
Name:
The influence of sex and histology ...
Size:
104.5Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record